We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Shares of Teva fell nearly 12% in pre-market trading to $16.80 after the company’s executives conceded during the fourth-quarter earnings report that 2019 would be an even tougher year than analysts had been expecting.